MISC - SHIMODA Kazuya
-
骨髄増殖性腫瘍の分子病態研究の進歩 ドライバー変異とエピゲノム異常の関わり
下田和哉
Hematopaseo 7 20 - 24 2020.8
Language：Japanese Publishing type：Article, review, commentary, editorial, etc. (scientific journal)
-
真性多血症、原発性骨髄線維症の病態と、JAK阻害薬ルキソリチニブの効果
幣光太郎、下田和哉
血液内科 81 ( 1 ) 8 - 13 2020.7
Language：Japanese Publishing type：Article, review, commentary, editorial, etc. (scientific journal)
-
骨髄増殖性腫瘍の病期進展メカニズム Invited
幣光太郎、下田和哉
血液内科 79 ( 6 ) 697 - 701 2019.12
Language：Japanese Publishing type：Article, review, commentary, editorial, etc. (scientific journal)
-
骨髄増殖性腫瘍におけるJAK阻害薬の使用基準
幣光太郎，下田和哉
血液内科 78 ( 6 ) 870 - 876 2019.6
Language：Japanese Publishing type：Article, review, commentary, editorial, etc. (scientific journal)
-
貧血を主症状とする低リスク骨髄異形成症候群の治療方針は?【輸血、サイトカイン療法、蛋白同化ステロイド、免疫抑制療法等が推奨される】
三谷絹子，下田 和哉
日本医事新報 ( 4963 ) 51 2019.6
Language：Japanese Publishing type：Article, review, commentary, editorial, etc. (scientific journal)
-
本態性血小板血症における出血傾向の機序と抗凝固療法の実際について
下田和哉、張替秀郎
日本医事新報 ( 4959 ) 50 2019.5
Language：Japanese Publishing type：Article, review, commentary, editorial, etc. (scientific journal)
-
慢性骨髄性白血病 Reviewed
下田和哉、高橋直人、川口辰哉、桐戸敬太、木崎昌弘
臨床血液 60 ( 3 ) 230 - 231 2019.5
Language：Japanese Publishing type：Article, review, commentary, editorial, etc. (scientific journal)
-
各科におけるステロイド療法のノウハウ
久冨木庸子，下田和哉
臨牀と研究 96 ( 4 ) 33 - 37 2019.4
Language：Japanese Publishing type：Article, review, commentary, editorial, etc. (scientific journal)
-
骨髄増殖性腫瘍（MPN） 治療の現状と今後の展望
Robert Kralovics, 下田和哉, 荒木真理人
血液フロンティア 29 ( 3 ) 90 - 93 2019.2
Language：Japanese Publishing type：Article, review, commentary, editorial, etc. (scientific journal)
-
The molecular pathogenesis of myeloproliferative neoplasms Reviewed
Shide Kotaro, Kameda Takuro, Shimoda Kazuya
Cytometry Research 28 ( 2 ) 7 - 12 2018.11
Language：Japanese Publishing type：Article, review, commentary, editorial, etc. (scientific journal)
-
骨髄増殖性腫瘍－WHO2016診断基準の改訂－ Reviewed
日高智徳，上運天綾子，下田和哉
臨床血液 59 ( 8 ) 1066 - 1071 2018.8
Language：Japanese Publishing type：Article, review, commentary, editorial, etc. (scientific journal)
-
骨髄増殖性腫瘍 治療最前線
上運天綾子、幣光太郎、下田和哉：
臨床血液 59 ( 6 ) 741 - 746 2018.6
Language：Japanese Publishing type：Article, review, commentary, editorial, etc. (scientific journal)
-
Recent advances in the diagnosis and management of primary myelofibrosis Reviewed
Takenaka K., Shimoda K., Akashi K.
Korean Journal of Internal Medicine 33 ( 4 ) 679 - 690 2018.4
Language：Japanese Publishing type：Article, review, commentary, editorial, etc. (bulletin of university, research institution) Publisher：Korean Journal of Internal Medicine
© 2018 The Korean Association of Internal Medicine. Primary myelofibrosis (PMF) is a myeloproliferative neoplasm (MPN) in which dysregulation of the Janus kinase/signal transducers and activators of transcription (JAK/STAT) signaling pathways is the major pathogenic mechanism. Most patients with PMF carry a driver mutation in the JAK2, MPL (myeloproliferative leukemia), or CALR (calreticulin) genes. Mutations in epigenetic regulators and RNA splicing genes may also occur, and play critical roles in PMF disease progression. Based on revised World Health Organization diagnostic criteria for MPNs, both screening for driver mutations and bone marrow biopsy are required for a specific diagnosis. Clinical trials of JAK2 inhibitors for PMF have revealed significant efficacy for improving splenomegaly and constitutional symptoms. However, the currently available drug therapies for PMF do not improve survival. Although allogeneic stem cell transplantation is potentially curative, it is associated with substantial treatment-related morbidity and mortality. PMF is a heterogeneous disorder and decisions regarding treatments are often complicated, necessitating the use of prognostic models to determine the management of treatments for individual patients. This review focuses on the clinical aspects and outcomes of a cohort of Japanese patients with PMF, including discussion of recent advances in the management of PMF.
-
肝硬変・門脈圧亢進症 Reviewed
土持舞衣、岩切久芳、下田和哉
宮崎県内科医会誌 ( 93 ) 18 - 21 2018.3
Language：Japanese Publishing type：Article, review, commentary, editorial, etc. (scientific journal)
-
The Role of Wild and Mutant Calreticulin in Hematopoiesis. Reviewed
下田和哉
血液フロンティア 28 ( 2 ) 218 - 220 2018.1
Language：English Publishing type：Article, review, commentary, editorial, etc. (scientific journal)
-
原発性および二次性骨髄線維症の本邦における特徴 Reviewed
幣光太郎、下田和哉
血液内科 76 ( 1 ) 59 - 65 2018.1
Language：Japanese Publishing type：Article, review, commentary, editorial, etc. (scientific journal)
-
血友病Aの新たな治療法 Invited
関根雅明、下田和哉
日本医事新報 ( 4880 ) 53 - 53 2017.11
Language：Japanese Publishing type：Article, review, commentary, editorial, etc. (scientific journal)
-
Mutant calreticulin causes essential thrombocythemia. Reviewed
Shimoda K, Shide K, Kameda T
Oncotarget. 8 ( 51 ) 88251 - 88252 2017.10
Language：English Publishing type：Article, review, commentary, editorial, etc. (scientific journal)
-
急性リンパ芽球性白血病治療の進歩 Invited
秋月渓一、下田和哉
日本医事新報 ( 4874 ) 51 - 51 2017.9
Language：Japanese Publishing type：Article, review, commentary, editorial, etc. (scientific journal)
-
成人T細胞白血病/リンパ腫(ATLL)に対するレナリドミド療法 Invited Reviewed
亀田拓郎、下田和哉
日本医事新報 2017.9
Language：Japanese Publishing type：Article, review, commentary, editorial, etc. (scientific journal)